$AMGN Company News Novartis wins FDA staff Ok for

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 11:24 AM

$AMGN Company News

Novartis wins FDA staff Ok for Neupogen generic 12:46 p.m. Jan. 5, 2015 - Marta Falconi
Amgen and Kite Pharma in cancer immunotherapy pact 10:00 a.m. Jan. 5, 2015 - Tess Stynes
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch

Company News for January 06, 2015 - Corporate Summary 10:10 a.m. Today - Zacks.com
Analysts' Actions: Domino's Pizza, General Electric, Michael Kors, Workday, More 9:41 a.m. Today - TheStreet.com
Secrets of the Year’s No. 1 Stock Fund 11:01 p.m. Jan. 5, 2015 - The Wall Street Journal Interactive Edition
Hot Biotech Stocks: Isis, Kite Jump On Big Deals 5:20 p.m. Jan. 5, 2015 - Investors Business Daily
Dow Tumbles on Oil, Europe Fears 4:41 p.m. Jan. 5, 2015 - The Wall Street Journal Interactive Edition
Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog 4:30 p.m. Jan. 5, 2015 - Zacks.com
Ad Comm approaches for Neupogen biosimilar 2:00 p.m. Jan. 5, 2015 - Seeking Alpha
3 Stocks Pushing The Drugs Industry Lower 1:10 p.m. Jan. 5, 2015 - TheStreet.com
Long Case For Amgen 12:42 p.m. Jan. 5, 2015 - Seeking Alpha
Novartis Wins FDA Staff OK for Neupogen Biosimilar 12:36 p.m. Jan. 5, 2015 - The Wall Street Journal Interactive Edition
Kite Pharma Up On Amgen Cancer Partnership 11:21 a.m. Jan. 5, 2015 - Investors Business Daily
Amgen, Kite Pharma in Immunotherapy Pact 10:29 a.m. Jan. 5, 2015 - The Wall Street Journal Interactive Edition
Amgen and Kite Pharma team up in CAR-T therapies 10:01 a.m. Jan. 5, 2015 - Seeking Alpha
Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More 8:31 a.m. Jan. 5, 2015 - benzinga.com
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 8:07 a.m. Jan. 5, 2015 - benzinga.com
Q4 2014 Update: Core Changes In My Whistler Income And Growth Portfolio 6:49 p.m. Jan. 4, 2015 - Seeking Alpha
My Dividend Portfolio: 2014 Q4 Update 8:18 a.m. Jan. 3, 2015 - Seeking Alpha
Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog 5:20 p.m. Jan. 2, 2015 - Zacks.com
Amgen Increases Dividend 30% And Has Had Lots Of Capital Appreciation During 2014 11:01 a.m. Jan. 2, 2015 - Seeking Alpha
45 Blue-Chip Dividend Stocks That Increased Payouts in Q4 2014 8:32 a.m. Jan. 2, 2015 - InvestorPlace.com

Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma 8:35 a.m. Dec. 31, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Dec. 17, 2014 - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Revamp Preschool Questions for Richer Conversations

Preschoolers, those tiny agents of chaos, come home with stories that you'd need a magnifying glass to find. Ask 'em "How was school?" and you're met with blank stares or a one-liner. Tami Nix of Archway Academy has been at this game for over 40 years, and she's got a trick or six up her sleeve. Ditch the Generic: Get Specific Yep, those generic questions are about as...

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Electra's Ultra Short Aircraft Revolutionizes Air Travel

From Tarmacs to Heliports: A New Era in Air Travel The aviation world doesn’t often see a sea change, but when a fixed-wing flyer touches down at a heliport, it grabs your attention. Electra’s recent leap into Manhattan’s Downtown Skyport highlights a promising shift in regional air mobility, doing away with the age-old reliance on long runways. It’s a shift that...

Pacsun Finds Gear: 177% Sales Surge at F1 Austin!

New Heights in Trackside Fashion Well, it looks like Pacsun's got a knack for making the Austin F1 scene as thrilling as the race itself, weaving fashion into the high-speed atmosphere. This year's Formula 1 United States Grand Prix in Austin brought a whopping 19% sales swell in 2026, marking a total sales increase of 177% since their initial 2023 Austin pop-up. Talk...

Everyday Innovation Shines at Canton Fair 2026

Subtle Brilliance in Daily Design You could be swimming in breakthrough tech and miss the real gems — like those sly innovators at this year's Canton Fair. They're overhauling the basics, making ordinary stuff extraordinary with a flick of the wrist. It’s not always the big flashy gadgets that steal the show; sometimes it’s the stealthy little tweaks. Knife...

STARMUS VIII: Bridging Science, Music, and Society

A Constellation of Luminaries at STARMUS You think you've seen it all on this spinning rock, and then something like STARMUS VIII comes around to shake up your perspective. From the Canary Islands, the world just got a little more interesting. We're talking a line-up that could humble the stars themselves—scientific pioneers, musical legends, and cultural icons all...

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

Sands China's Latest Move: A Bond Offering Twist

Breaking Down Sands China's Bond Maneuver Today, we found out that Sands China is teeing up a fresh round of senior unsecured notes. Now, if that doesn't get your ticker flickin', maybe you're too used to market snoozefests. The folks at the helm of Sands China, a subsidiary under the mighty Las Vegas Sands Corp. (NYSE: LVS), are rolling out these USD-denominated notes...

Landis+Gyr's Big Contract Victory: A Game Changer?

Diving into Landis+Gyr's Major Utility Win When news hits about a deal secured by Landis+Gyr Group AG, it rings a few bells across the utility landscape. These folks have brewed up a storm with a fresh contract that slots into their rapidly expanding portfolio of grid-savvy products. So, what’s the fuss about this latest agreement? A Groundbreaking Contract Now, this...

3TREES Debuts Green Coatings to East African Market

3TREES Rocks East Africa's Construction Scene Nairobi's got a spark this week, and it's radiating straight from 3TREES' corner at the Big 5 Construct Kenya. With the Sarit Expo Centre buzzing from October 21, 2026, this Chinese company didn't just show up—they made one hell of an entrance. Presenting eco-friendly coating solutions, they pushed the 'Create Healthy Life'...